Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS212 + JS207 + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
JS212 + JS207 + capecitabine + oxaliplatin is a combination therapy being developed by Shanghai Junshi Bioscience for the treatment of previously untreated microsatellite stable (MSS) or proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC). The regimen consists of four components: JS212, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3 with a topoisomerase I inhibitor payload; JS207, a recombinant humanized bispecific antibody targeting PD-1 and VEGF; and the XELOX chemotherapy regimen, which includes capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum-based agent). JS212 is designed to overcome resistance to EGFR-directed therapies through dual targeting, while JS207 provides simultaneous immune checkpoint blockade and anti-angiogenesis. This combination is currently being evaluated in a Phase 2 clinical trial to assess its safety, tolerability, pharmacokinetics, and preliminary antitumor activity.
- Other names
- JS212 + JS207 + XELOX
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)DNAEGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on JS212 + JS207 + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS212 + JS207 + capecitabine + oxaliplatin.